Cannabinoids are a group of chemicals that come from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have suggest that it has anti inflammatory effects when induced in animals. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychotropic effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to bind and do their job in the body. This paper will look at how cannabinoids can be used in the central nervous system (CNS) to treat neuropathic pain.
Here is the full scientific article if you wish to download it.
Cannabinoid 2 receptor, a target for treating neuropathic pain?
In this experiment, AM1241, a specific CB2 cannabinoid receptor agonist, is used to test the idea that CB2 receptor triggering would stop the sensory hypersensitivity seen in neuropathic pain conditions. AM1241 shows high affinity and selectivity for CB2 receptors. AM1241 dose-dependently stopped tactile and thermal hypersensitivity promoted in spinal nerves in rats. These impacts were specifically antagonized by a CB2 but not by a CB1 receptor antagonist, suggesting that they were made by actions of AM1241 at CB2 receptors. AM1241 was also working in preventing spinal nerve ligation-induced tactile and thermal hypersensitivity in mice that don’t have CB1 receptors, concluding that AM1241 stops sensory hypersensitivity independent of actions at CB1 receptors. These results demonstrate an action leading to the induction of pain, one that targets receptors localized specifically outside the CNS. Further, they say the possible use of CB2 receptor specific agonists for treating of chronic pain, a syndrome currently without known efficient therapies. CB2 receptor selective agonist prescriptions are said to be without the CNS adverse events that prevent the effectiveness of currently available prescriptions.
Cannabinoids have anti inflammatory effects
The conclusion seen in this paper gives evidence that CB2 receptor selective agonists may be efficient in treating chronic pain without CNS adverse events. Such a therapeutic profile gives massive advantages over recent therapies. More so, the value of CB2 receptor selective agonists, such as AM1241, in pain therapy is increased by their seen efficiency against inflammation and neuropathic pain. Although multiple pain actions may be working in the same patient with cancer pain, there are currently no single therapies that are available and effective against these vast categories of pain. This data suggests the value of the development of CB2 receptor selective agonists for human therapeutics.